Search

Displaying results 1661 - 1670 of 10000 in total
  1. Drug

    Prednisolone acetate

    go.drugbank.com/drugs/DB15566
    ApprovedInvestigationalVet approved

    Prednisolone acetate is a [prednisolone] molecule bound to an acetate functional group by an ester bond.[L9449] Prednisolone acetate was granted FDA approval in 1955.[L9449]

  2. Drug

    Teriparatide

    go.drugbank.com/drugs/DB06285
    ApprovedInvestigational

    [A251395] Teriparatide is used in the treatment of osteoporosis in men and women.[L42590, L42595] … [A251395] First approved in the United States in November 2002 and in Europe in April 2003,[A251400] teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic

    Products: SONDELBAY (Teriparatide) 20 micrograms/ 80 microliters solution for injection in pre-filled pen, Teriparatid ratiopharm 20 Mikrogramm/80 Mikroliter Injektionslösung in einem vorgefüllten Injektor
  3. Drug

    Clostridium tetani

    go.drugbank.com/drugs/DB09876
    ApprovedInvestigational

    Mixtures: Boostrix Injektionssuspension in einer Fertigspritze, Boostrix Polio - Injektionssuspension in einer Fertigspritze
  4. Drug

    GC-376 free acid

    go.drugbank.com/drugs/DB15796
    Experimental

    A prodrug of [GC-373], GC-376 has recently been used to test inhibition of SARS-Cov-2 M<sup>pro</sup> _in vitro_, and results show potent inhibition of this target[A219036]. … In addition, GC-376 displays potent activity against various coronaviruses such as feline, ferret, and mink M<sup>pro</sup> coronavirus[A219026,A219031,A219036,A219041].

  5. Drug

    Metyrosine

    go.drugbank.com/drugs/DB00765
    ApprovedInvestigational

    It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) … An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines.

  6. Drug

    Insulin degludec

    go.drugbank.com/drugs/DB09564
    ApprovedInvestigational

    [A18561,A18562,A18563,A18564,A174934] Insulin is an essential treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas … [A18561,A18562,A18563,A18564,A174934] As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin degludec, to lower glucose levels in the blood.

    Mixtures: Xultophy Pre-filled PenCategories: Drugs Used in Diabetes
  7. Drug

    Alogliptin

    go.drugbank.com/drugs/DB06203
    ApprovedInvestigational

    It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.

    Categories: Drugs Used in Diabetes
  8. Drug

    Oxymetazoline

    go.drugbank.com/drugs/DB00935
    ApprovedInvestigational

    [L15057] In July 2020, the FDA approved the use of an ophthalmic formulation of oxymetazoline (Upneeq) in adults with acquired blepharoptosis, or ptosis, making it the first FDA-approved medical treatment … [A215587, L15092] In dentistry, oxymetazoline and tetracaine combination intranasal spray (Kovanaze) is used for regional anesthesia during dental procedures in children and adults.

    Mixtures: N-S-4Products: n-Drops NASAL DECONGESTANT
  9. Drug

    Tretinoin

    go.drugbank.com/drugs/DB00755
    ApprovedInvestigationalNutraceutical

    [A257474] It is an oxidation product in the physiological pathway of vitamin A metabolism. … [A257689] In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L.

    Categories: Retinoids for Topical Use in AcneSynonyms: all-(E)-Retinoic acid, (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
  10. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]